Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.
about
A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer.Sunitinib does not impair natural killer cell function in patients with renal cell carcinoma.Sunitinib enhances the antitumor responses of agonistic CD40-antibody by reducing MDSCs and synergistically improving endothelial activation and T-cell recruitment
P2860
Clinical response to sunitinib as a multitargeted tyrosine-kinase inhibitor (TKI) in solid cancers: a review of clinical trials.
description
2014 nî lūn-bûn
@nan
2014 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Clinical response to sunitinib ...... : a review of clinical trials.
@ast
Clinical response to sunitinib ...... : a review of clinical trials.
@en
type
label
Clinical response to sunitinib ...... : a review of clinical trials.
@ast
Clinical response to sunitinib ...... : a review of clinical trials.
@en
prefLabel
Clinical response to sunitinib ...... : a review of clinical trials.
@ast
Clinical response to sunitinib ...... : a review of clinical trials.
@en
P2093
P2860
P356
P1476
Clinical response to sunitinib ...... : a review of clinical trials.
@en
P2093
Lian Zhang
Sungkyoung Kim
Wenping Ding
P2860
P304
P356
10.2147/OTT.S61388
P407
P577
2014-05-12T00:00:00Z